A Phase 3 interventional study of IBI362 and Placebo in Overweight, Obesity and Hypertensive, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.
Among the 22 studies testing mazdutide in Obesity, this one is the 7th largest by planned enrollment, is one of 8 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 1 of the 13 other live ones, and was the 15th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18–60
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 12–18
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, mazdutide is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 6 · Phase 4 2
First in 2020; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 336 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 187 across the 22 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 8 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
16 studies in Obesity by Innovent Biologics, Inc.: 5 open now, 9 under way, 4 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 16 studies in Obesity by Innovent Biologics, Inc., this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 6 in phase 3, and was the 14th registered.
Innovent Biologics, Inc.’s Obesity studies by the year they started, since 2020.
3 of the studies testing mazdutide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06931028Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | 2027-05-07 |
| NCT07255209Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | 2027-10-31 |
| NCT06143956Eli Lilly and CompanyA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing mazdutide in Obesity, from their registry updates:
Among Innovent Biologics, Inc.’s 16 in Obesity:
This tab as a report to print or save as PDF → With an account.
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's planned enrollment of 336 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: IBI362
Drug: Placebo
IBI362 will be administered subcutaneously once weekly (QW) in a step-up dose titration regimen over 48 weeks: * Weeks 1-4: 2 mg QW * Weeks 5-8: 4 mg QW * Weeks 9-24: 6 mg QW * Weeks 25-48: 6/9 mg QW.
Matching placebo will be administered subcutaneously once weekly (QW) for 48 weeks, with the same number of injections as the IBI362 group to maintain study blinding.
To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment.
Change from baseline in msSBP at trough (end-of-dosing interval) at Week 16
Time frame: Week 16
To evaluate the effect of IBI362 on Mean Sitting Systolic Arterial Pressure(msSBP) compared with placebo at Week 24 of treatment.
Change from baseline in Mean Sitting Systolic Arterial Pressure(msSBP) at Week 24.
Time frame: Week 24
To evaluate the effect of IBI362 on body weight compared with placebo at Weeks 16 and 24 of treatment.
Percent change from baseline in body weight at Weeks 16 and 24.
Time frame: Week 16 and Week 24
To evaluate the trough-to-peak ratio of the antihypertensive effect of IBI362 on Mean Sitting Systolic Arterial Pressure(msSBP)and Mean Sitting Diastolic Arterial Pressure(msDBP)at Week 16 of treatment.
Trough-to-peak ratio of the antihypertensive effect on Mean Sitting Systolic Arterial Pressure(msSBP)and Mean Sitting Diastolic Arterial Pressure(msDBP) calculated by ABPM at Week 16.
Time frame: Week 16
The effects of IBI362 on Mean Sitting Systolic Arterial Pressure(msSBP) compared to placebo were evaluated at each node during treatment.
At Weeks 4, 8, 12, and 48, changes in msSBP from baseline.
Time frame: Week 4, 8, 12, and 48
The effects of IBI362 on mean sitting diastolic arterial pressure (msDBP) compared to placebo were evaluated at each node during treatment.
Changes from baseline in msDBP at Weeks4, 8, 12, 16, 24, and 48.
Time frame: Week 4, 8, 12, 16, 24, and 48
The effects of IBI362 on mean arterial pressure (MAP) compared to placebo were evaluated at each node during treatment.
At Weeks 4, 8, 12, 16, 24, and 48, the change of MAP from baseline.
Time frame: Week 4, 8, 12, 16, 24, and 48
The effect of IBI362 on blood pressure reduction efficacy and compliance compared to placebo was evaluated at each node during treatment.
At weeks 4, 8, 12, 16, 24, 48, the proportion of participants with an effective rate of msSBP \<140 mmHg and msDBP\<90 mmHg, or a reduction of ≥20 mmHg from baseline in msSBP and/or a decrease in diastolic blood pressure of ≥10 mmHg from baseline in msDBP and not on risk-based salvage therapy.
Time frame: Week 4, 8, 12, 16, 24, 48
The effect of IBI362 on blood pressure reduction efficacy and compliance compared to placebo was evaluated at each node during treatment.
At weeks 4, 8, 12, 16, 24, and 48, the rate of blood pressure reduction: the proportion of participants with msSBP\<140 mmHg and msDBP\<90 mmHg without risk-based salvage therapy.
Time frame: Week 4, 8, 12, 16, 24, and 48
The effect of IBI362 on blood pressure reduction efficacy and compliance compared to placebo was evaluated at each node during treatment.
Proportion of participants initiating risk-based remedial treatment at each visit.
Time frame: Week 4, 8, 12, 16, 24, and 48
The effect of IBI362 on blood pressure reduction efficacy and compliance compared to placebo was evaluated at each node during treatment.
Proportion of participants initiating remedial treatment based on blood pressure compliance at each visit.
Time frame: Week 4, 8, 12, 16, 24, and 48
The effects of IBI362 on 24-hour of Ambulatory Blood Pressure Monitoring (ABPM) compared with placebo were evaluated at each node during treatment.
At weeks 8, 12, 16, 24, and 48, the average SBP and mean DBP were changed from baseline during the whole monitoring period monitored by ABPM.
Time frame: Week 8, 12, 16, 24, and 48
The effects of IBI362 on day-to-night mean SBP and mean DBP of Ambulatory Blood Pressure Monitoring (ABPM) compared with placebo were evaluated at each node during treatment.
Changes from baseline in daytime and nighttime mean SBP and mean DBP monitored by ABPM at weeks 8, 12, 16, 24, and 48.
Time frame: Week 8, 12, 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on body weight compared with placebo.
Percent change in body weight from baseline at week 48.
Time frame: Week 48
During treatment, IBI362 was evaluated for the effects of IBI362 on body weight compared with placebo.
At 16, 24, and 48 weeks, changes in weight from baseline.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on body mass index (BMI) compared with placebo.
At 16, 24, and 48 weeks, changes in BMI from baseline.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on waist circumference compared with placebo.
At 16, 24, and 48 weeks, changes in waist circumference from baseline.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on fasting blood glucose compared with placebo.
At 16, 24, and 48 weeks, fasting blood glucose changed from baseline.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on glycated hemoglobin (HbA1c) compared with placebo.
At 16, 24, and 48 weeks, HbA1c changed from baseline.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on total cholesterol (TC).
Changes from baseline in total cholesterol (TC) at 16, 24, and 48 weeks.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on low-density lipoprotein cholesterol (LDL-C) compared with placebo.
Changes from baseline in low-density lipoprotein cholesterol (LDL-C) at 16, 24, and 48 weeks.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on high-density lipoprotein cholesterol (HDL-C) compared with placebo.
Changes from baseline in high-density lipoprotein cholesterol (HDL-C) at 16, 24, and 48 weeks.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on non-high-density lipoprotein (non-HDL-C) compared with placebo.
Changes from baseline in non-high-density lipoprotein (non-HDL-C) at 16, 24, and 48 weeks.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on very low-density lipoprotein cholesterol (VLDL-C) compared with placebo.
Changes from baseline in very low-density lipoprotein cholesterol (VLDL-C) at 16, 24, and 48 weeks.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on triglycerides (TG) compared with placebo.
Changes from baseline in triglycerides (TG) at 16, 24, and 48 weeks.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on Lp(a) compared with placebo.
Changes from baseline in Lp(a) at 16, 24, and 48 weeks.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on Apo B compared with placebo.
Changes from baseline in Apo B at 16, 24, and 48 weeks.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on estimated glomerular filtration rate (eGFR) compared with placebo.
At weeks 16, 24, and 48, the changes in eGFR from baseline.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on urine protein compared with placebo.
At weeks 16, 24, and 48, the changes in urine albumin/creatinine ratio from baseline.
Time frame: Week 16, 24, and 48
During treatment, IBI362 was evaluated for the effects of IBI362 on cystatin-C compared with placebo.
Week 16, 24, and 48
Time frame: Change from baseline in cystatin-C at 16, 24, and 48 weeks.
During treatment, IBI362 was evaluated for the effects of IBI362 on blood uric acid compared with placebo.
At 16, 24, and 48 weeks, the change in blood uric acid from baseline.
Time frame: Week 16, 24, and 48
Started Apr 2026 (actual). Primary completion is estimated for Aug 2026, 3 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 3 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mazdutide
Innovent Biologics (Suzhou) Co. Ltd. →